HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Acute Myeloid Leukemia
Interventions
GENETIC

HLA mismatched stem cell

HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy

GENETIC

HLA matched stem cell

HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen

DRUG

cyclosporine A

The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil

DRUG

Mycophenolate mofetil

The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil

DRUG

Ara-C

2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose

DRUG

fludarabine

30 mg/m2/d for 5days

DRUG

anti-lymphocyte globulin

1.5-2 mg/kg/d for 4 days

DRUG

cyclophosphamide

40 mg/kg/d for 2 days

Trial Locations (1)

100071

Affiliated Hospital of Academy of Military Medical Sciences ,, Beijing

All Listed Sponsors
lead

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

OTHER

NCT02461121 - HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | Biotech Hunter | Biotech Hunter